Dizdarevic, S.Tulchinsky, M.McCready, V.R.Mihailovic, J,Vinjamuri, S.Buscombe, J.R.Lee, S.T.Frangos, S.Sathekge, Mike MachabaSiraj, Q.Choudhury, P.Bom, H.Franceschi, M.Ugrinska, A.Paez, D.Hussain, R.Mailman, J.Luster, M.Virgolini, I.2020-09-102020-09-102019-04Dizdarevic, S., Tulchinsky, M., McCready, V.R. et al. 2019, 'The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma', World Journal of Nuclear Medicine, vol. 18, no. 2, pp. 123-126.1450-1147 (print)1607-3312 (online)10.4103/wjnm.WJNM_117_18http://hdl.handle.net/2263/76135The World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) is a worldwide nonprofit organization, which is dedicated to educating medical professionals in the use of radionuclide therapies based on the theragnostic principles and to harmonizing appropriate evidence‑based practices worldwide.en© 2019 World Journal of Nuclear Medicine. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License.CancerWorld Association of Radiopharmaceutical and Molecular Therapy (WARMTH)Radioiodine therapyThyroid carcinomaArticle